This post was originally published on this site Recent immunosuppression, which causes a drop in CD4 T-cell levels, and prolonged exposure to high HIV viral load are two independent predictors of non-Hodgkin’s lymphoma among people living with HIV, a recent study shows. While these two measures also predicted the risk of diffuse large B-cell lymphoma (DLBCL)…
This post was originally published on this site Combining radiation therapy with immune checkpoint inhibitors induces an immune response to both irradiated and non-irradiated glioblastoma, a study in mice found, suggesting that a combination of these approaches could improve survival outcomes for those patients. The findings were presented recently at the 2019 American Association of…
This post was originally published on this site Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) seeking the approval of its androgen receptor inhibitor Erleada (apalutamide) for patients with metastatic castration-sensitive prostate cancer (CSPC). The supplemental new drug application is based on data from the ongoing Phase 3 TITAN clinical trial…
This post was originally published on this site Too few women with ovarian cancer and breast cancer are getting the recommended genetic tests that help evaluate their risk of developing other cancers – which could guide changes in their clinical care – according to a population-based study done in California and Georgia. The discrepancy is…
This post was originally published on this site A triple regimen composed of Kyprolis (carfilzomib), thalidomide, and dexamethasone, given before and after high-dose chemotherapy and autologous stem cell transplant, is safe and highly effective for the treatment of newly diagnosed multiple myeloma, results of a Phase 2 clinical trial show. The study, “Phase 2 Study…
This post was originally published on this site Since her diagnosis of metastatic breast cancer two years ago, Karen Peterson has been amid a whirlwind of medical appointments and healthcare professionals. It’s often overwhelming. “Managing it all is like a job,” the 54-year-old New York City resident said in an interview with Breast Cancer News.…
This post was originally published on this site A new imaging-guided surgical technique that makes ovarian cancer tumors glow under near-infrared light can help surgeons remove tumors as small as 0.3 millimeters, a study in mice shows. The approach also increased mice’s lifespan by 40% compared to mice treated with standard non-imaging-guided surgery. Researchers are…
This post was originally published on this site Forty Seven and Genentech are extending their agreement to include a third clinical trial evaluating a combination of the investigational 5F9 plus Rituxan (rituximab) and Tecentriq (atezolizumab) in patients with diffuse large B-cell lymphoma (DLBCL). The decision builds on prior Phase 1b data, where a combination of 5F9 and Rituxan was safe and eliminated tumors in one-third of DLBCL patients…
This post was originally published on this site Sound Biologics is launching a Phase 1 trial to test its candidate immunotherapy PSB205 in relapsed or refractory solid tumor patients, after the U.S. Food and Drug Administration cleared its investigational new drug (IND) application. The product is a combination of antibodies against the PD-1 and CTLA-4 factors…
This post was originally published on this site A new imaging technique that visualizes individual cells with high resolution may improve the understanding of key events in breast cancer development, including how and when cells turn invasive and spread elsewhere. The tool, which already has helped explain mechanisms used by cancer cells to evade treatment, was…
